Abbvie Inc.
A global biopharmaceutical company, AbbVie develops and sells medicines for immune, nerve, and cancer conditions — brands include Skyrizi, Rinvoq, Humira, Botox, and Imbruvica — as well as cosmetic treatments like Botox Cosmetic and the Juvederm line. It was born in 2013 when Abbott Laboratories split, spinning off its drug business into a fresh company. Fun fact: the name blends "Abb" (from Abbott) with "Vie," echoing the Latin word for "life," and insiders noted it conveniently rhymes with "R&D."
Granted 4.21M · Sold 2.48M
Granted 1.38M · Bought 25.0K · Sold 906.4K
Granted 489.8K · Bought 30.0K · Sold 243.0K
Granted 801.7K · Sold 319.9K
Granted 497.8K · Sold 129.1K
Granted 425.7K · Bought 30.4K · Sold 188.3K
Granted 724.8K · Sold 505.5K
Granted 1.16M · Sold 748.8K
Granted 13.1K
Granted 106.7K · Sold 74.6K
Granted 169.7K
Granted 467.4K · Bought 15.6K · Sold 284.3K
Granted 103.1K · Bought 7.5K · Sold 37.3K
Granted 96.7K · Sold 21.7K
Granted 28.1K · Bought 17.9K
Granted 39.8K
Granted 27.0K · Bought 5.4K
Granted 174.2K · Sold 113.6K
Granted 28.1K · Bought 76.5K · Sold 78.1K
Granted 142.6K · Sold 47.7K
Granted 27.0K
Granted 79.7K · Bought 5.3K · Sold 30.9K
Granted 28.1K · Bought 2.0K
Granted 28.1K
Granted 103.4K · Sold 40.2K
Granted 7.5K
Granted 21.6K
Granted 20.6K
Granted 17.6K
Granted 158.8K · Sold 121.4K
Granted 14.8K
Granted 2.5K
Granted 38.5K · Sold 25.9K
Granted 772.9K · Sold 592.8K
Granted 2.3K
Granted 3.6K
Granted 3.6K
Granted 6.1K · Sold 5.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Gonzalez Richard ADirector · 319 transactions | — | 386.5Kas of Mar 2025 | 4.21M | — | 2.48M |
| Schumacher Laura JVice Chairman · 128 transactions | — | 248.0Kas of Feb 2022 | 1.38M | 25.0K | 906.4K |
| Gosebruch Henry OEVP, Chief Strategy Officer · 86 transactions | — | 246.5Kas of May 2022 | 489.8K | 30.0K | 243.0K |
| Saleki-Gerhardt AzitaEVP, CHIEF OPERATIONS OFFICER · 127 transactions | — | 204.4K | 801.7K | — | 319.9K |
| Michael Robert A.CHAIRMAN OF THE BOARD AND CEO, Director · 57 transactions | — | 178.7K | 497.8K | — | 129.1K |
| Chase William JEVP, Finance & Administration · 45 transactions | — | 170.1Kas of Jun 2019 | 425.7K | 30.4K | 188.3K |
| Alban CarlosVice Chairman · 54 transactions | — | 155.3Kas of Nov 2020 | 724.8K | — | 505.5K |
| Severino MichaelVice Chairman · 69 transactions | — | 152.1Kas of May 2022 | 1.16M | — | 748.8K |
| Freyman Thomas CDirector · 8 transactions | — | 133.8K | 13.1K | — | — |
| Leonard John M.SVP, Chief Scientific Officer · 9 transactions | — | 113.8Kas of Mar 2013 | 106.7K | — | 74.6K |
| Hudson Thomas JSVP, CSO, GLOBAL RESEARCH · 25 transactions | — | 107.3Kas of Feb 2024 | 169.7K | — | — |
| Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICER · 66 transactions | — | 84.5K | 467.4K | 15.6K | 284.3K |
| Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER · 24 transactions | — | 74.4K | 103.1K | 7.5K | 37.3K |
| Hurwich Thomas A.VP, Controller · 39 transactions | — | 70.1Kas of Mar 2017 | 96.7K | — | 21.7K |
| Rapp Edward JDirector · 28 transactions | — | 56.4K | 28.1K | 17.9K | — |
| Thakkar RoopalEVP, R&D and CSO · 15 transactions | — | 55.4K | 39.8K | — | — |
| Tilton Glenn FDirector · 14 transactions | — | 51.9Kas of May 2025 | 27.0K | 5.4K | — |
| Sorg Elaine K.SVP, US COMMERCIAL OPERATIONS · 42 transactions | — | 41.5Kas of Apr 2023 | 174.2K | — | 113.6K |
| Austin Roxanne SDirector · 23 transactions | — | 39.6K | 28.1K | 76.5K | 78.1K |
| Reents Scott TEVP, CHIEF FINANCIAL OFFICER · 25 transactions | — | 38.8K | 142.6K | — | 47.7K |
| Alpern Robert JDirector · 14 transactions | — | 35.6Kas of May 2025 | 27.0K | — | — |
| Durkin Brian LVP, CONTROLLER · 37 transactions | — | 33.1Kas of Feb 2023 | 79.7K | 5.3K | 30.9K |
| Waddell Frederick HDirector · 15 transactions | — | 30.1K | 28.1K | 2.0K | — |
| Burnside William H.L.Director · 14 transactions | — | 28.1K | 28.1K | — | — |
| Strom Carrie CSVP & PRES GLOBAL ALLERG AESTH · 37 transactions | — | 28.0Kas of May 2023 | 103.4K | — | 40.2K |
| Roberts Roy SDirector · 3 transactions | — | 27.5Kas of May 2015 | 7.5K | — | — |
| Liddy Edward MDirector · 9 transactions | — | 26.7Kas of May 2021 | 21.6K | — | — |
| Hart Brett JDirector · 11 transactions | — | 20.6K | 20.6K | — | — |
| Meyer Melody BDirector · 10 transactions | — | 17.6K | 17.6K | — | — |
| Siatis Perry CEVP, GC AND SECRETARY · 51 transactions | — | 17.5K | 158.8K | — | 121.4K |
| Roberts Rebecca BDirector · 9 transactions | — | 14.8K | 14.8K | — | — |
| Crum Demetris DEVP, CHIEF HR OFFICER · 3 transactions | — | 7.9K | 2.5K | — | — |
| Buckbee Kevin KSVP, CONTROLLER · 17 transactions | — | 7.8Kas of Feb 2025 | 38.5K | — | 25.9K |
| Richmond Timothy J.EVP, CHIEF HR OFFICER · 103 transactions | — | 6.1Kas of Mar 2025 | 772.9K | — | 592.8K |
| Falk Thomas JDirector · 2 transactions | — | 5.3K | 2.3K | — | — |
| Davis Jennifer L.Director · 3 transactions | — | 3.6K | 3.6K | — | — |
| Quaggin Susan EDirector · 3 transactions | — | 3.6K | 3.6K | — | — |
| Purdue David RyanSVP, Controller · 6 transactions | — | 1.1K | 6.1K | — | 5.2K |
| Abbott Laboratories10% owner · 1 transaction | — | 0as of Dec 2012 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -6.78M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.